Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-6382
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India ; volume:10 ; number:4 ; day:27 ; month:7 ; year:2021 ; pages:2271-2288 ; date:12.2021
Infectious diseases and therapy ; 10, Heft 4 (27.7.2021), 2271-2288, 12.2021
- Urheber
-
Ghia, Canna J.
Horn, Emily K.
Rambhad, Gautam
Perdrizet, Johnna
Chitale, Ramaa
Wasserman, Matt D.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40121-021-00498-4
- URN
-
urn:nbn:de:101:1-2022012020475766376967
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ghia, Canna J.
- Horn, Emily K.
- Rambhad, Gautam
- Perdrizet, Johnna
- Chitale, Ramaa
- Wasserman, Matt D.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules
Strengths and weaknesses of pneumococcal conjugate vaccines
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: a case report
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules
Strengths and weaknesses of pneumococcal conjugate vaccines
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: a case report
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules
Strengths and weaknesses of pneumococcal conjugate vaccines
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: a case report
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001